title: Long-term evolution of cytophagic histiocytic panniculitis.
abstract: BACKGROUND
  Cytophagic histiocytic panniculitis is a disorder manifested by multiple subcutaneous nodules, characterized by lobular panniculitis, and occasionally accompanied by severe systemic manifestations, which require an aggressive medical approach. Several case reports with a good response to immunosuppressive therapy in the acute phase can be found in the literature.
  
  
  CONCLUSIONS
  Nevertheless, the long-term evolution of this entity has not been described yet, nor have precise recommendations regarding the most adequate posology and duration of therapy. We report the result of switching from a long-term cyclosporine therapy to tacrolimus in a patient with a severe form of cytophagic histiocytic panniculitis.
authors.affiliation: Autoimmune Diseases Unit and Department of Pathology, Hospital Clinico de San Cecilio, Granada, Spain.
authors.forename: Raquel
authors.initials: R
authors.lastname: Rios Fernández
authors.forename: José-Luis
authors.initials: JL
authors.lastname: Callejas Rubio
authors.forename: Daniel
authors.initials: D
authors.lastname: Sánchez Cano
authors.forename: Juan-Ramón
authors.initials: JR
authors.lastname: Dominguez Vicent
authors.forename: Juan
authors.initials: J
authors.lastname: Linares Solano
authors.forename: Norberto
authors.initials: N
authors.lastname: Ortego Centeno
mesh_terms: D005260:Female; D006644:Histiocytes / Q000473:pathology; D015614:Histiocytosis / Q000473:pathology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008875:Middle Aged; D015434:Panniculitis / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D011241:Prednisone / Q000008:administration & dosage; D016559:Tacrolimus / Q000008:administration & dosage*
chemical_list: D007166:Immunosuppressive Agents; D011241:Prednisone; D016559:Tacrolimus